Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW LTE: Enpatoran in SCLE, DLE, and/or SLE
NCT05540327Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2022
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE) (3 arms), sponsored by Merck KGaA. Primary endpoint: Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events, Adverse Event of Special Interest at 50 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT05540327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540327.